Breaking News, Collaborations & Alliances

Bora Biologics, DotBio Enter Strategic CMC Development Collaboration

Bora will support CMC strategy through to clinical development for DotBio’s tri-specific antibody to treat cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bora Biologics, a division of CDMO Bora Pharmaceuticals, will support DotBio, a biopharmaceutical company specializing in next-gen antibody therapies, in the development and manufacture of DotBio’s lead asset, a novel tri-specific antibody, DB007, against undisclosed cancer targets. Bora will support chemistry, manufacturing, and controls (CMC) strategy through to clinical development from its 48,400-sq.-ft. center of excellence in Zhubei, Taiwan. “Bora Biologics offers a tailored developm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters